Skip to main content
. 2022 Jan 17;11:e68832. doi: 10.7554/eLife.68832

Appendix 1—figure 8. Contrast between gene list and pathway-level connections.

Appendix 1—figure 8.

Comparison of insulin resistance-drug repurposing (IR-DR) drug signature genes with 73 knock-down/overexpression (KD/OE) validated proteins from the positively acting IR-DR drug list. This demonstrates that while (A) no individual validated protein targets were in the drug repurposing signature, many belonged to pathways that contained the known drug targets (B). Blue lines connect common pathways.